Lorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Eliglustat | The metabolism of Eliglustat can be decreased when combined with Lorvotuzumab mertansine. |
| Ibrutinib | The metabolism of Ibrutinib can be decreased when combined with Lorvotuzumab mertansine. |
| Alfentanil | The serum concentration of Alfentanil can be increased when it is combined with Lorvotuzumab mertansine. |
| Buspirone | The metabolism of Buspirone can be decreased when combined with Lorvotuzumab mertansine. |
| Carbamazepine | The metabolism of Carbamazepine can be decreased when combined with Lorvotuzumab mertansine. |
| Cisapride | The serum concentration of Cisapride can be increased when it is combined with Lorvotuzumab mertansine. |
| Disopyramide | Lorvotuzumab mertansine may increase the QTc-prolonging activities of Disopyramide. |
| Estazolam | The serum concentration of Estazolam can be increased when it is combined with Lorvotuzumab mertansine. |
| Quinine | The serum concentration of Quinine can be increased when it is combined with Lorvotuzumab mertansine. |
| Quinidine | The serum concentration of Quinidine can be increased when it is combined with Lorvotuzumab mertansine. |
| Repaglinide | The serum concentration of Repaglinide can be increased when it is combined with Lorvotuzumab mertansine. |
| Sirolimus | The metabolism of Sirolimus can be decreased when combined with Lorvotuzumab mertansine. |
| Temsirolimus | The metabolism of Temsirolimus can be decreased when combined with Lorvotuzumab mertansine. |
| Terfenadine | The serum concentration of Terfenadine can be increased when it is combined with Lorvotuzumab mertansine. |
| Triazolam | The serum concentration of Triazolam can be increased when it is combined with Lorvotuzumab mertansine. |
| Cilostazol | The metabolism of Cilostazol can be decreased when combined with Lorvotuzumab mertansine. |
| Colchicine | The metabolism of Colchicine can be decreased when combined with Lorvotuzumab mertansine. |
| Iloperidone | The metabolism of Iloperidone can be decreased when combined with Lorvotuzumab mertansine. |
| Retapamulin | The metabolism of Retapamulin can be decreased when combined with Lorvotuzumab mertansine. |
| Tofacitinib | The metabolism of Tofacitinib can be decreased when combined with Lorvotuzumab mertansine. |
| Vardenafil | The metabolism of Vardenafil can be decreased when combined with Lorvotuzumab mertansine. |
| Eszopiclone | The metabolism of Eszopiclone can be decreased when combined with Lorvotuzumab mertansine. |
| Zopiclone | The metabolism of Zopiclone can be decreased when combined with Lorvotuzumab mertansine. |
| Lovastatin | The metabolism of Lovastatin can be decreased when combined with Lorvotuzumab mertansine. |
| Alfuzosin | The metabolism of Alfuzosin can be decreased when combined with Lorvotuzumab mertansine. |
| Alprazolam | The serum concentration of Alprazolam can be increased when it is combined with Lorvotuzumab mertansine. |
| Warfarin | The serum concentration of Warfarin can be increased when it is combined with Lorvotuzumab mertansine. |
| Acenocoumarol | The serum concentration of Acenocoumarol can be increased when it is combined with Lorvotuzumab mertansine. |
| (R)-warfarin | The serum concentration of (R)-warfarin can be increased when it is combined with Lorvotuzumab mertansine. |
| R,S-Warfarin alcohol | The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Lorvotuzumab mertansine. |
| S,R-Warfarin alcohol | The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Lorvotuzumab mertansine. |
| (S)-Warfarin | The serum concentration of (S)-Warfarin can be increased when it is combined with Lorvotuzumab mertansine. |
| Midazolam | The serum concentration of Midazolam can be increased when it is combined with Lorvotuzumab mertansine. |
| Tacrolimus | The serum concentration of Tacrolimus can be increased when it is combined with Lorvotuzumab mertansine. |
| Telaprevir | The serum concentration of Telaprevir can be increased when it is combined with Lorvotuzumab mertansine. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Lorvotuzumab mertansine. |
| Estrone | Estrone may increase the thrombogenic activities of Lorvotuzumab mertansine. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Lorvotuzumab mertansine. |
| Estriol | Estriol may increase the thrombogenic activities of Lorvotuzumab mertansine. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Lorvotuzumab mertansine. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Lorvotuzumab mertansine. |
| Tibolone | Tibolone may increase the thrombogenic activities of Lorvotuzumab mertansine. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Lorvotuzumab mertansine. |
| Zeranol | Zeranol may increase the thrombogenic activities of Lorvotuzumab mertansine. |
| Equol | Equol may increase the thrombogenic activities of Lorvotuzumab mertansine. |
| Promestriene | Promestriene may increase the thrombogenic activities of Lorvotuzumab mertansine. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Lorvotuzumab mertansine. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Lorvotuzumab mertansine. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Lorvotuzumab mertansine. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Lorvotuzumab mertansine. |
| Formononetin | Formononetin may increase the thrombogenic activities of Lorvotuzumab mertansine. |
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Lorvotuzumab mertansine. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Lorvotuzumab mertansine. |
| Estradiol | Estradiol may increase the thrombogenic activities of Lorvotuzumab mertansine. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Lorvotuzumab mertansine. |
| Mestranol | Mestranol may increase the thrombogenic activities of Lorvotuzumab mertansine. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Lorvotuzumab mertansine. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Lorvotuzumab mertansine. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Lorvotuzumab mertansine. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Lorvotuzumab mertansine. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Lorvotuzumab mertansine. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Lorvotuzumab mertansine. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Lorvotuzumab mertansine. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Lorvotuzumab mertansine. |
| Picosulfuric acid | The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Lorvotuzumab mertansine. |
| Vintafolide | The serum concentration of Vintafolide can be increased when it is combined with Lorvotuzumab mertansine. |
| Vincamine | The serum concentration of Vincamine can be increased when it is combined with Lorvotuzumab mertansine. |
| Acetyldigitoxin | The serum concentration of Acetyldigitoxin can be increased when it is combined with Lorvotuzumab mertansine. |
| Deslanoside | The serum concentration of Deslanoside can be increased when it is combined with Lorvotuzumab mertansine. |
| Ouabain | The serum concentration of Ouabain can be increased when it is combined with Lorvotuzumab mertansine. |
| Oleandrin | The serum concentration of Oleandrin can be increased when it is combined with Lorvotuzumab mertansine. |
| Cymarin | The serum concentration of Cymarin can be increased when it is combined with Lorvotuzumab mertansine. |
| Proscillaridin | The serum concentration of Proscillaridin can be increased when it is combined with Lorvotuzumab mertansine. |
| Metildigoxin | The serum concentration of Metildigoxin can be increased when it is combined with Lorvotuzumab mertansine. |
| Lanatoside C | The serum concentration of Lanatoside C can be increased when it is combined with Lorvotuzumab mertansine. |
| Gitoformate | The serum concentration of Gitoformate can be increased when it is combined with Lorvotuzumab mertansine. |
| Acetyldigoxin | The serum concentration of Acetyldigoxin can be increased when it is combined with Lorvotuzumab mertansine. |
| Peruvoside | The serum concentration of Peruvoside can be increased when it is combined with Lorvotuzumab mertansine. |
| Cyclosporine | The metabolism of Cyclosporine can be decreased when combined with Lorvotuzumab mertansine. |
| Dicoumarol | The serum concentration of Dicoumarol can be increased when it is combined with Lorvotuzumab mertansine. |
| Phenindione | The serum concentration of Phenindione can be increased when it is combined with Lorvotuzumab mertansine. |
| Coumarin | The serum concentration of Coumarin can be increased when it is combined with Lorvotuzumab mertansine. |
| Tioclomarol | The serum concentration of Tioclomarol can be increased when it is combined with Lorvotuzumab mertansine. |
| Ethyl biscoumacetate | The serum concentration of Ethyl biscoumacetate can be increased when it is combined with Lorvotuzumab mertansine. |
| Diphenadione | The serum concentration of Diphenadione can be increased when it is combined with Lorvotuzumab mertansine. |
| 4-hydroxycoumarin | The serum concentration of 4-hydroxycoumarin can be increased when it is combined with Lorvotuzumab mertansine. |
| Fluindione | The serum concentration of Fluindione can be increased when it is combined with Lorvotuzumab mertansine. |
| Clorindione | The serum concentration of Clorindione can be increased when it is combined with Lorvotuzumab mertansine. |
| Oxtriphylline | The metabolism of Oxtriphylline can be decreased when combined with Lorvotuzumab mertansine. |
| Doxofylline | The metabolism of Doxofylline can be decreased when combined with Lorvotuzumab mertansine. |
| Bamifylline | The metabolism of Bamifylline can be decreased when combined with Lorvotuzumab mertansine. |
| Acefylline | The metabolism of Acefylline can be decreased when combined with Lorvotuzumab mertansine. |
| Bufylline | The metabolism of Bufylline can be decreased when combined with Lorvotuzumab mertansine. |
| Fenethylline | The metabolism of Fenethylline can be decreased when combined with Lorvotuzumab mertansine. |
| Proxyphylline | The metabolism of Proxyphylline can be decreased when combined with Lorvotuzumab mertansine. |
| Bromotheophylline | The metabolism of Bromotheophylline can be decreased when combined with Lorvotuzumab mertansine. |
| Pentoxifylline | The metabolism of Pentoxifylline can be decreased when combined with Lorvotuzumab mertansine. |
| 8-azaguanine | The metabolism of 8-azaguanine can be decreased when combined with Lorvotuzumab mertansine. |
| 7,9-Dimethylguanine | The metabolism of 7,9-Dimethylguanine can be decreased when combined with Lorvotuzumab mertansine. |
| Xanthine | The metabolism of Xanthine can be decreased when combined with Lorvotuzumab mertansine. |